Top Markets
#1 B3 (Base) B3 (Base) +14.17%
#2 Janction Janction +12.47%
#3 DMT-NAT DMT-NAT +11.90%
#4 Fake World Assets Fake World Assets +11.22%
#5 TENDIES TENDIES +6.21%
#6 Status Status +4.85%
#7 GoPlus Security GoPlus Security +4.76%
#8 龙虾 (Lobster) 龙虾 (Lobster) +4.30%
#9 Provenance Blockchain Provenance Blockchain +3.88%
#10 Everything Everything +3.72%
Coin of the day
B3 (Base) B3 (Base)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Clasificación en acciones #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Precio por acción
$0.6379482
Última sincronización: 2023-05-22
Capitalización bursátil
$5.98M
Cambio (1 día)
-0.44%
Cambio (1 año)
0.00%
País
FR
Comercio Nicox S.A. (COX)

Categoría

Healthcare
Ganancias de Nicox S.A. (COX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Nicox S.A., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Nicox S.A. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE